Daiichi Sankyo Europe GmbH

Featured Stories

For the last nine years Daiichi Sankyo has supported young graduates in Pharmaceutical Sciences from the Ludwig-Maximilians-University in Munich (LMU). In 2017, Kristina Eiglmeier and Martin Müller were awarded the "Master Prize" read more...

The new Daiichi Sankyo Group’s Value Report is now available! The report includes business facts & figures, information about Daiichi Sankyo’s growth potential, CSR activities and much more. read more...

Featured News

Date	Description
10/12/2018 Research	Daiichi Sankyo Presents Updated Phase 1 Results of [Fam-] Trastuzumab Deruxtecan (DS-8201) in Patients with HER2 Low Expressing Metastatic Breast Cancer at 2018 San Antonio Breast Cancer Symposium (SABCS)	PDF
06/12/2018 Research	Daiichi Sankyo Presents Updated Phase 1 Data for U3-1402 in Patients with HER3-Expressing Metastatic Breast Cancer at 2018 San Antonio Breast Cancer Symposium (SABCS)	PDF
04/12/2018 Press EU	Comprehensive Analyses from Pivotal Phase 3 QuANTUM-R Study Demonstrate Consistent Overall Survival Benefit of Daiichi Sankyo’s FLT3 Inhibitor Quizartinib in Patients with Relapsed/Refractory FLT3-ITD AML	PDF
27/11/2018 Research	Daiichi Sankyo and Roche to Collaborate on New HER2 Low Companion Diagnostic Test	PDF
21/11/2018 Research	FDA Grants Priority Review for Daiichi Sankyo’s New Drug Application for FLT3 Inhibitor Quizartinib for Treatment of Patients with Relapsed/Refractory FLT3-ITD AML	PDF
show all

Dear User, This website provides you with information only for healthcare professionals. According to the drug promotion code, we are only able to allow healthcare professionals like physicians and pharmacists to have full access to our website. To visit our page please login.

Daiichi Sankyo
Doc Check

Support for Young Talents

Value Report 2018